Allergan plc (NYSE:AGN.PRA) Q1 2016 Earnings Conference Call - Final Transcript
May 10, 2016 • 08:30 am ET
Good morning. My name is Lashonda, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan First Quarter 2016 Earnings Conference Call. [Operator Instructions]
Thank you. I will now turn today's call over to Lisa DeFrancesco, Vice President of Investor Relations, to begin. Please go ahead.
Lisa M. DeFrancesco
Thank you, Lashonda. And good morning, everyone. I'd like to welcome you to the Allergan First Quarter 2016 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan's earnings from continuing operations for the first quarter ended March 31, 2016. The press release and our slide deck which we are presenting this morning are available on our corporate website at www.allergan.com. We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyrighted material of Allergan and cannot be rebroadcast without the Company's expressed written consent.
Turning to Slide 2, I'd also like to remind you that during the course of this call management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements and reflect our current perspective of the business trends and information as of today's date.
Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Allergan business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements except as expressly required by law.
Turning to Slide 3 in our agenda this morning, with us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our first quarter business highlights; Bill Meury, our Chief Commercial Officer, who will provide an overview of our commercial performance in the quarter; David Nicholson, our Chief R&D Officer, who will provide highlights from our pipeline achievements in 2016 and upcoming milestones; Rob Stewart, our Chief Operating Officer, who will provide a few highlights on our Global Generics business; and Tessa Hilado, our Chief Financial Officer, who will then discuss the Allergan's first quarter continuing operations results in more detail. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; and Bob Bailey, our Chief Legal Officer.
With that, I'll turn it over to Brent.
Brenton L. Saunders
Thank you, Lisa, and good morning, everyone. Beginning on Slide 5, Allergan remains the most dynamic and exciting company in our industry. And in my mind, that makes us the best pharmaceutical company in the world. You can see it in our results this quarter. You can see it in the way our team has pivoted to focus on our future as a standalone leader in Growth Pharma. You can see it in the operational excellence on display in teams across our company. You can see it in